



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 January 2015
EMA/654663/2014

Agenda – Industry Stakeholder platform - Operation of EU pharmacovigilance legislation

12 January 2015, 09:30-13:45, Meeting room 02-F

Chair: Peter Arlett, Head of Pharmacovigilance

Item	Preliminary draft agenda	Time
1.	Welcome and matters arising <ul style="list-style-type: none">– Peter Arlett, Head of Pharmacovigilance, EMA– June M Raine, PRAC Chair	09:30
2.	Risk Management Planning follow up to September meeting <ul style="list-style-type: none">• RMPs (follow up from previous meeting)<ul style="list-style-type: none">– Luis Prieto, EMA• RMPs for Nationally authorised products<ul style="list-style-type: none">– Kora Doorduyn - van der Stoep, CMDh• Industry feedback• Discussion and next steps	09:40
3.	Post-Authorisation Safety Studies (PASS), Update from the regulators <ul style="list-style-type: none">• Experience to date<ul style="list-style-type: none">– Almath Spooner, PRAC Vice Chair• Encouraging joint studies<ul style="list-style-type: none">– Irene Rager, Head of Evaluation Procedures E, EMA• Role of ENCePP<ul style="list-style-type: none">– Henry Fitt, Best Evidence Development Head, EMA• Transparency	10:30
Coffee Break		11:15
3.	Post-Authorisation Safety Studies (PASS), Update from the regulators (2nd part) <ul style="list-style-type: none">• Scientific Advice<ul style="list-style-type: none">– Peter Arlett, Head of Pharmacovigilance, EMA– Jane Moseley, Scientific Advice, Product Development Scientific Support, EMA– Corinne De Vries, Risk Management Specialist, EMA	11:30



Item	Preliminary draft agenda	Time
	<ul style="list-style-type: none"> Registries initiative <ul style="list-style-type: none"> Xavier Kurz, Head of Monitoring and Incidence Management Service, Pharmacovigilance Department, EMA Industry feedback Discussion and next steps 	
4.	Post-Authorisation Efficacy Studies (PAES) <ul style="list-style-type: none"> Update on the development of scientific and regulatory guidance <ul style="list-style-type: none"> Jane Moseley EMA Tomas Salmonson, CHMP 	12:15
5.	Q & A on Off-Label Use <ul style="list-style-type: none"> Update on progress from EudraVigilance Expert Group <ul style="list-style-type: none"> Anja van Haren, MBA and co-chair EV-EWG TC Sabine Brosch, EMA and co-chair EV-EWG 	12:45
6.	Update on development of pharmacovigilance information systems <ul style="list-style-type: none"> PSUR repository, Article 57, EudraVigilance, Literature Monitoring, Fees: contact via the QPPV <ul style="list-style-type: none"> Peter Arlett, Head of Pharmacovigilance, EMA Irene Rager, Head of Evaluation Procedures E, EMA 	13:00
7.	General Discussion and agreement on next steps <ul style="list-style-type: none"> June M Raine, PRAC Chair Peter Arlett, Head of Pharmacovigilance, EMA 	13:15
8.	Close of meeting	13:45